A Study of the Effect of Bran, Psyllium and Nopal on Intestinal Water Content Using Magnetic Resonance Imaging (NOPAL)

April 16, 2019 updated by: University of Nottingham

A Pilot Participant-blind Study of the Effect of Bran, Psyllium and Nopal on Intestinal Water Content Using Magnetic Resonance Imaging

This study will compare 3 food products (bran, psyllium and nopal) on intestinal water content measured via MRI.

Study Overview

Detailed Description

BACKGROUND AND RATIONALE

The role of dietary fibre in human health is a topic of both debate and research. Interpreting evidence is complicated by changes in the definition of fibre. In the UK the Scientific Advisory Committee for Nutrition has recently proposed a definition of "all carbohydrates that are neither digested nor absorbed in the small intestine and have a degree of polymerisation of three or more monomeric units, plus lignin". They have also called for further research into the physiological effects of fibre of the gastrointestinal (GI) tract.

The Nottingham GI MRI group has been at the forefront of elucidating the effects of poorly digested carbohydrates on gastrointestinal physiology. The investigators have published techniques to measure free water in the small bowel and assessment of the physical form of chyme in the colon using MR relaxometry. This includes the demonstration that fructose ingestion on its own leads to increased free water in the small bowel compared to co-ingestion with glucose.

Bran is often confused with dietary fibre. Although it contains fibre, the term actually refers to the outer husk of seeds and grains. It has been shown to accelerate oro-caecal transit (OCT) with scintigraphy. Bran can also be shown to increase small bowel water content, possibly by mechanical stimulation, one of the most powerful stimuli for small intestinal secretion, which may be a mechanism to prevent blockage. In the past bran's high fibre content led to the hypothesis that its effect derived from holding water in the lumen but a comparison study of 17 different fibres found an inverse relationship between their water-holding properties and effect on faecal weight, with bran holding the least water but inducing the largest weight changes. Rather, weight change appeared to relate to the amount of undigested fibre present in the faeces and the associated changes in bacterial numbers, which account for most of dry stool weight.

In contrast, psyllium husk contains a fibre that binds water effectively. On this basis it has been used as a laxative for thousands of years. In fact, there is little evidence that psyllium accelerates whole gut transit time as might be expected of a laxative. Work within the investigating group has shown that psyllium increases water in both the small bowel and the faeces, leading to softer, looser stool.

Nopal is a Mexican dietary product derived from cactus. It contains a different mix of fibre, 2/3rds of which is insoluble like bran fibre and 1/3rd soluble like psyllium. It is the subject of several health claims. The investigating group has recently been awarded a grant by the Newton Fund, through the Medical Research council, to study its effects on gut function. The aim of the Newton Fund is to stimulate collaborative research with middle-income countries such as Mexico. Part of the project plan is to invite a Mexican radiologist, Dr Alfonso Gil-Valadez, to Nottingham to learn about the MRI techniques used by our group.

TRIAL OBJECTIVES AND PURPOSE

Purpose

The purpose of the study is to gather pilot data on the effect of Nopal on intestinal water content, in comparison to bran and psyllium.

Objective

The primary objective is to gather pilot data on the change from baseline in small bowel water content in healthy volunteers after a meal containing nopal, in comparison to meals containing psyllium or bran.

Secondary Objectives

Secondary objectives will be to gather pilot data on the effects of the fibre-containing meals on the physical form of colonic chyme, colonic volume and breath markers of fermentation.

Hypotheses

The test meals will lead to differences in post-prandial water in the small bowel.

The test meals will lead to differences in the post-prandial volume and physical composition of chyme in the colon.

The test meals will not lead to change in breath markers of fermentation.

Study Type

Interventional

Enrollment (Actual)

12

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Nottinghamshire
      • Nottingham, Nottinghamshire, United Kingdom, NG7 2UH
        • University of Nottingham

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Aged 18 or older
  • Able to give informed consent

Exclusion Criteria:

  • Pregnancy declared by candidate
  • History declared by the candidate of pre-existing gastrointestinal disorder that may affect bowel function
  • A positive diagnosis of irritable bowel syndrome based on the Rome IV criteria questionnaire
  • Reported history of previous resection of the oesophagus, stomach or intestine (excluding appendix)
  • Intestinal stoma
  • Any medical condition making participation potentially compromising participation in the study e.g. diabetes mellitus, respiratory disease limiting ability to lie in the scanner, known allergy to one of the food products
  • Contraindications for MRI scanning i.e. metallic implants, pacemakers, history of metallic foreign body in eye(s) and penetrating eye injury
  • Will not agree to dietary restrictions required in 24 hours before each MRI study day
  • Unable to stop drugs known to alter GI motility including mebeverine, opiates, monoamine oxidase inhibitors, phenothiazines, benzodiazepines, calcium channel antagonists for the duration of the study (Selective serotonin reuptake inhibitors and low dose tricyclic antidepressants will be recorded but will not be an exclusion criteria)
  • Inability to lie flat or exceed scanner limits of weight <120kg
  • Poor understanding of English language
  • Participation in night shift work the week prior to the study day. Night work is defined as working between midnight and 6.00 AM
  • Participation in any medical trials for the past 3 months
  • Anyone who in the opinion of the investigator is unlikely to be able to comply with the protocol e.g. cognitive dysfunction, chaotic lifestyle related to substance abuse

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Nopal added to test meal
test meal including nopal powder
220g rice pudding meal with raspberry jam with added nopal flakes
Experimental: Psyllium added to test meal
test meal including psyllium powder
220g rice pudding meal with raspberry jam with added psyllium flakes
Experimental: Bran added to test meal
test meal including bran powder
220g rice pudding meal with raspberry jam with added bran flakes

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change from the baseline in T1 relaxation time (ms) of the chyme in the ascending colon
Time Frame: baseline, immediately post ingestion, 1, 2, 3 and 4 hours post ingestion
measured by MRI
baseline, immediately post ingestion, 1, 2, 3 and 4 hours post ingestion

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change from the baseline in small bowel water content (mL)
Time Frame: baseline, immediately post ingestion, 1, 2, 3 and 4 hours post ingestion
measured by MRI
baseline, immediately post ingestion, 1, 2, 3 and 4 hours post ingestion
Change from the baseline in colonic volume in mL
Time Frame: baseline, immediately post ingestion, 1, 2, 3 and 4 hours post ingestion
measured by MRI
baseline, immediately post ingestion, 1, 2, 3 and 4 hours post ingestion
Change from the baseline of breath hydrogen and methane (ppm)
Time Frame: baseline, immediately post ingestion, 1, 2, 3 and 4 hours post ingestion
measured using GastroCHeck
baseline, immediately post ingestion, 1, 2, 3 and 4 hours post ingestion

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Robin Spiller, PhD, University of Nottingham

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 18, 2018

Primary Completion (Actual)

October 1, 2018

Study Completion (Actual)

November 1, 2018

Study Registration Dates

First Submitted

August 21, 2017

First Submitted That Met QC Criteria

August 25, 2017

First Posted (Actual)

August 28, 2017

Study Record Updates

Last Update Posted (Actual)

April 17, 2019

Last Update Submitted That Met QC Criteria

April 16, 2019

Last Verified

May 1, 2018

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • NOPAL

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Constipation

Clinical Trials on Nopal

3
Subscribe